What is Mutabilis?
Mutabilis is a French biopharmaceutical company dedicated to the discovery and development of novel antibacterial agents targeting Gram-negative infections. The company possesses unique expertise in diazabicyclooctane chemistry, which is instrumental in creating new antibacterials and beta-lactamase inhibitors. These compounds exhibit significant stability against hydrolysis by both serine and metallo-beta-lactamases, positioning them as promising candidates for treating highly resistant infections, including those unresponsive to carbapenems.
How much funding has Mutabilis raised?
Mutabilis has raised a total of $7M across 1 funding round:
Private Equity
$7M
Private Equity (2020): $7M with participation from REPAIR Impact Fund
Key Investors in Mutabilis
REPAIR Impact Fund
The REPAIR Impact Fund is an investor focused on addressing the global challenge of antimicrobial resistance.
What's next for Mutabilis?
The substantial enterprise-level funding indicates a significant growth phase for Mutabilis. This capital infusion is expected to accelerate the company's research and development pipeline, potentially advancing its novel antibacterial candidates through clinical trials. The strategic nature of the recent investment suggests a strong belief from backers in Mutabilis's technology and its potential to address the critical unmet need for effective treatments against multidrug-resistant Gram-negative bacteria.
See full Mutabilis company page
